[
    [
        {
            "time": "2019-03-06",
            "original_text": "After Hours Most Active for Mar 6, 2019: GE, LLY, WBA, WRE, BAC, V, SHY, S, SBUX, AAPL, QQQ, PACB",
            "features": {
                "keywords": [
                    "after hours",
                    "most active",
                    "LLY",
                    "GE"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "After Hours Most Active for Mar 6, 2019: GE, LLY, WBA, WRE, BAC, V, SHY, S, SBUX, AAPL, QQQ, PACB",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-03-06",
            "original_text": "Lilly's Emgality Gets FDA Priority Review for Cluster Headache",
            "features": {
                "keywords": [
                    "Emgality",
                    "FDA",
                    "priority review",
                    "cluster headache"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's Emgality Gets FDA Priority Review for Cluster Headache",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-06",
            "original_text": "J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression",
            "features": {
                "keywords": [
                    "JNJ",
                    "Spravato",
                    "FDA",
                    "depression"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-06",
            "original_text": "3 Big Pharmas Trying to Pop the Rebate Bubble",
            "features": {
                "keywords": [
                    "big pharmas",
                    "rebate bubble"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3 Big Pharmas Trying to Pop the Rebate Bubble",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-06",
            "original_text": "FDA Approves Major Novel Depression Drug For First Time In 3 Decades",
            "features": {
                "keywords": [
                    "FDA",
                    "novel drug",
                    "depression",
                    "approval"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "FDA Approves Major Novel Depression Drug For First Time In 3 Decades",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-06",
            "original_text": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Eli Lilly",
                    "report"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]